InvetigLab Shares Surge Over 7% on Expectations of International Patent Filing for Ultra-High-Concentration Antibody Subcutaneous Injection and Presentation at US Conference (PODD 2026)
InvetigLab is drawing investor attention with a gain of more than 7%. As news spread of its international patent filing for subcutaneous injection formulation technology for ultra-high-concentration antibody drugs and its plan to present research results at a global conference, attention is focusing

InvetigLab is drawing investor attention with a gain of more than 7%. As news spread of its international patent filing for subcutaneous injection formulation technology for ultra-high-concentration antibody drugs and its plan to present research results at a global conference, attention is focusing on the commercialization potential of its drug delivery platform.
On the 14th, InvetigLab was trading at 25,050 won, up 1,700 won from the previous day, a rise of about 7.28%. As the intraday gain widened, the company's next-generation drug delivery technology emerged as a major point of interest.
◆ International PCT Patent Filing Completed for Ultra-High-Concentration Antibody Subcutaneous Injection Technology
InvetigLab previously announced that it has completed an international patent filing (PCT) for technology related to 'IVL-BioFluidic®,' its subcutaneous injection formulation platform for ultra-high-concentration antibody drugs. The technology focuses on a formulation platform that enables high-dose antibody drugs to be administered via subcutaneous injection within a limited delivery volume.
Antibody drugs are sometimes administered intravenously depending on dosage and formulation characteristics. Converting to subcutaneous injection formulations could improve administration time and convenience in clinical settings, but this requires solving several technical challenges. In particular, stability issues that may arise when increasing antibody concentration, changes in particle characteristics, injection resistance during administration, long-term storage stability, and reproducibility of the manufacturing process must all be managed comprehensively.
The IVL-BioFluidic platform being developed by InvetigLab is an ultra-high-concentration antibody formulation technology designed to address these technical challenges. The company is focusing on the possibility that the technology could serve as a next-generation platform that complements or expands the scope of existing hyaluronidase-based subcutaneous formulation technologies.
◆ Global Competition in High-Concentration Formulation Technology
Competition over high-concentration biologics and subcutaneous injection formulation technology continues in the global market. Halozyme, a global drug delivery company, is expanding its related technology portfolio through the acquisitions of Elektrofi and Surf Bio. These cases show that technology enhancing the convenience of antibody drug administration is emerging as an important development area in the pharmaceutical and biotech industries.
However, global companies' moves to secure technology do not directly prove InvetigLab's technological competitiveness or future contract deals. In this field, commercialization is considered to depend not only on the performance of individual technologies but also on the scope of patent rights, stability of manufacturing processes, and scalability for mass production.
◆ Points of Caution Regarding Patents and Contracts
The PCT international patent filing completed by InvetigLab is significant as a step toward protecting its technology. However, the international filing itself does not mean that patent rights have been obtained in individual countries; actual rights will depend on the examination results in each country.
The oral presentation scheduled at PODD 2026 could serve as an opportunity to introduce the company's research results to the global pharmaceutical and biotech industries. If research content is presented on the specific performance and manufacturing reproducibility of the ultra-high-concentration antibody formulation technology, it is expected to serve as reference material for evaluating the platform's technical feasibility.
However, a conference presentation does not immediately lead to technology transfer or joint development contracts with global pharmaceutical companies. To confirm follow-up business results, actual contract signings and development progress must be monitored.
◆ Key Points to Watch
With InvetigLab's share price rising to 25,050 won on the 14th, future market attention is expected to focus on the technological validation of the IVL-BioFluidic platform, intellectual property protection, and the possibility of partnerships with global pharmaceutical companies. Beyond the short-term stock price rise, the key element to watch going forward is whether R&D achievements can translate into tangible business results.
[This article was written based on intraday market prices provided and InvetigLab's announcements. Intraday share prices are subject to change, and technology development and commercialization outlooks may differ from actual results. An international patent filing does not guarantee patent registration or the securing of rights. This article is not a recommendation to invest in any particular stock, and investment decisions and responsibilities rest with the investor. This article was written with the assistance of AI.]
CBC Globe publishes verified stories with editorial review, source checks, and tenant-specific publication standards.


![[Breaking] Evernos Holdings (XRPN) Flat at $7.45... Bitcoin at $64,922, Market on Alert Over Weakness in Leading Stock](/_next/image?url=https%3A%2F%2Fmedia.cbcglobe.com%2Ftenants%2Fcbc00000-0000-4000-8000-000000000001%2Fmedia%2Fcbc%2F2026%2F11%2F626848%2F4c15339f3668573e%2Fvariants%2Fhero.webp&w=1920&q=75)
